NextCure

NXTC · NASDAQ

$5.44−$0.23 (−4.06%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $5.67

About NXTC

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company is headquartered in Beltsville, Maryland and currently employs 40 full-time employees. The company went IPO on 2019-05-09. The company focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.

Employees: 40
Headquarters: Beltsville, Maryland
Listed: May 9, 2019
Sector: Health Care
Industry: Biotechnology
Website: nextcure.com

Leadership

NextCure executives
Name	Title	Since	Age
David Kabakoff	—	—	77
Michael Richman	—	2015	64
Steven Cobourn	—	2018	62
Timothy Mayer	—	—	61
Kevin Shaw	—	—	51
Sourav Kundu	—	—	65
Solomon Langermann	—	—	65
Udayan Guha	—	—	53
Anne Borgman	—	—	57
Ellen Feigal	—	—	71
John Houston	—	—	65
Elaine Jones	—	—	70
Stephen Webster	—	—	64

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

NextCure suppliers and customers
Company	Relationship	Country	Correlation
Yale University	Supplier and customer	US	—

Similar companies

Companies in the same industry as NextCure

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.